Clinical Trial Update: Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating decitabine in combination with penpulimab as second-line therapy for advanced esophageal squamous cell carcinoma after PD-1 blockade.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• decitabine + penpulimab

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN